INCY insider buying and SEC filings, explained
Incyte Corp. · CIK 879169
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$58.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 2,642 shares at $112.71 ($298K), marked as a 10b5-1 plan trade. Holdings down 1% to 183,200 shares. | SEC filing Filed Oct 19, 2026, 4:38 PM ET |
| Sep 15, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 23,218 shares at about $120.49 ($2.8M), marked as a 10b5-1 plan trade. Holdings down 11% to 183,200 shares. | SEC filing Filed Sep 17, 2026 |
| Aug 19, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 10,801 shares at $125.56 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 6% to 183,200 shares. | SEC filing Filed Aug 20, 2026 |
| Aug 12, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 10,803 shares at $120.04 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 5% to 194,001 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 5, 2026 | Planned (10b5-1) | Patrick A Mayes (EVP & Chief Scientific Officer) sold 2,207 shares at $123.99 ($274K), marked as a 10b5-1 plan trade. Holdings down 3% to 61,441 shares. | SEC filing Filed Aug 7, 2026 |
| Aug 5, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 10,640 shares at $122.69 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 5% to 204,804 shares. | SEC filing Filed Aug 7, 2026 |
| Jul 31–Aug 3, 2026 | Planned (10b5-1) | Patrick A Mayes (EVP & Chief Scientific Officer) sold 47,954 shares between Jul 31 and Aug 3 at about $119.58 ($5.7M), marked as a 10b5-1 plan trade. Holdings down 44% to 61,441 shares. | SEC filing Filed Aug 4, 2026 |
| Jul 31, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 15,888 shares at $119.70 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 7% to 215,444 shares. | SEC filing Filed Aug 4, 2026 |
| Jul 16, 2026 | Planned (10b5-1) | Mohamed Khairie Issa (EVP, Head of U.S. Commercial) sold 1,093 shares at $115.01 ($126K), marked as a 10b5-1 plan trade. Holdings down 2% to 63,940 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 16, 2026 | Planned (10b5-1) | Steven H Stein (CMO & Head of Late-Stage Dev.) sold 1,877 shares at $114.73 ($215K), marked as a 10b5-1 plan trade. Holdings down 8% to 21,118 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Steven H Stein (CMO & Head of Late-Stage Dev.) sold 28,237 shares at $113.05 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 52% to 26,083 shares. | SEC filing Filed Jul 16, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Thomas Tray (Principal Accounting Officer) sold 2,639 shares at $100.00 ($264K), marked as a 10b5-1 plan trade. Holdings down 11% to 21,132 shares. | SEC filing Filed Jun 8, 2026 |
| May 26, 2026 | Planned (10b5-1) | Thomas Tray (Principal Accounting Officer) sold 2,051 shares at $97.35 ($200K), marked as a 10b5-1 plan trade. Holdings down 9% to 21,132 shares. | SEC filing Filed May 28, 2026 |
| May 19, 2026 | Planned (10b5-1) | Paul J Clancy (Director) sold 15,000 shares at $94.93 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 39% to 23,741 shares. | SEC filing Filed May 21, 2026 |
| Apr 17, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 18,667 shares at $96.50 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 7% to 262,692 shares. | SEC filing Filed Apr 21, 2026 |
| Mar 17, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 18,667 shares at $94.24 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 7% to 234,800 shares. | SEC filing Filed Mar 19, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Pablo J. Cagnoni (President / COO) sold 18,668 shares at $100.91 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 7% to 234,800 shares. | SEC filing Filed Feb 23, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Mohamed Khairie Issa (EVP, Head of US Oncology) sold 10,856 shares at $109.07 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 14% to 66,132 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Steven H Stein (EVP & Chief Medical Officer) sold 15,634 shares at $101.70 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 31% to 34,203 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 18–19, 2025 | Planned (10b5-1) | Thomas Tray (Principal Accounting Officer) sold 3,374 shares between Dec 18, 2025 and Dec 19, 2025 at about $99.69 ($336K), marked as a 10b5-1 plan trade. Holdings down 13% to 22,973 shares. | SEC filing Filed Dec 22, 2025 |
| Dec 16–17, 2025 | Planned (10b5-1) | Michael James Morrissey (EVP, Head of Tech. Operations) sold 58,331 shares between Dec 16, 2025 and Dec 17, 2025 at about $97.29 ($5.7M), marked as a 10b5-1 plan trade. Holdings down 68% to 27,507 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 10–11, 2025 | Planned (10b5-1) | Patrick A Mayes (EVP & Chief Scientific Officer) sold 5,808 shares between Dec 10, 2025 and Dec 11, 2025 at about $95.55 ($555K), marked as a 10b5-1 plan trade. Holdings down 9% to 60,011 shares. | SEC filing Filed Dec 12, 2025 |
| Dec 1–2, 2025 | Planned (10b5-1) | Steven H Stein (EVP & Chief Medical Officer) sold 22,664 shares between Dec 1, 2025 and Dec 2, 2025 at about $102.56 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 26% to 63,129 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 21–24, 2025 | Planned (10b5-1) | Thomas Tray (Principal Accounting Officer) sold 769 shares between Nov 21, 2025 and Nov 24, 2025 at about $102.78 ($79K), marked as a 10b5-1 plan trade. Holdings down 3% to 23,573 shares. | SEC filing Filed Nov 25, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Sheila A. Denton (EVP & General Counsel) sold 278 shares at $104.36 ($29K), marked as a 10b5-1 plan trade. Holdings down 1% to 26,569 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 10, 2025 | Planned (10b5-1) | Herve Hoppenot (Director) sold 187,500 shares at $105.46 ($19.8M), marked as a 10b5-1 plan trade. Holdings down 36% to 329,646 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Steven H Stein (EVP & Chief Medical Officer) sold 5,233 shares at $102.20 ($535K), marked as a 10b5-1 plan trade. Holdings down 5% to 102,886 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Sheila A. Denton (EVP & General Counsel) sold 598 shares at $101.36 ($61K), marked as a 10b5-1 plan trade. Holdings down 2% to 26,569 shares. | SEC filing Filed Nov 6, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Lee Heeson (EVP, Head of Incyte Intl) sold 3,074 shares at $94.02 ($289K), marked as a 10b5-1 plan trade. Holdings down 10% to 29,241 shares. | SEC filing Filed Nov 5, 2025 |
80 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow INCY in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.